EverSource Wealth Advisors
PVLA icon

EverSource Wealth Advisors’s Palvella Therapeutics PVLA Stock Holding History

EverSource Wealth Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53K Buy
10
+3
+43% +$364 ﹤0.01% 3824
2026
Q1 		$873 Buy
+7
New +$730 ﹤0.01% 3900

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

EverSource Wealth Advisors's PVLA Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Palvella Therapeutics (PVLA) stake by 43% in Q2 2026, buying an estimated $364 and bringing the position to 10 shares worth $1.53K. The position accounts for ﹤0.01% of the portfolio, ranked #3824.

EverSource Wealth Advisors first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • EverSource Wealth Advisors held 10 shares of Palvella Therapeutics worth $1.53K as of Q2 2026.
  • EverSource Wealth Advisors bought 3 Palvella Therapeutics shares in Q2 2026, an estimated $364.
  • Palvella Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3824 holding.
  • EverSource Wealth Advisors first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.